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Ion channels modulate ion flux across cell membranes, activate signal transduction
pathways, and influence cellular transport—vital biological functions that are inexorably
linked to cellular processes that go awry during carcinogenesis. Indeed, deregulation of ion
channel function has been implicated in cancer-related phenomena such as unrestrained
cell proliferation and apoptotic evasion. As the prototype for ligand-gated ion channels,
nicotinic acetylcholine receptors (nAChRs) have been extensively studied in the context of
neuronal cells but accumulating evidence also indicate a role for nAChRs in carcinogenesis.
Recently, variants in the nAChR genes CHRNA3, CHRNA5, and CHRNB4 have been
implicated in nicotine dependence and lung cancer susceptibility. Here, we silenced the
expression of these three genes to investigate their function in lung cancer. We show that
these genes are necessary for the viability of small cell lung carcinomas (SCLC), the most
aggressive type of lung cancer. Furthermore, we show that nicotine promotes SCLC cell
viability whereas an α3β4-selective antagonist, α-conotoxin AuIB, inhibits it. Our findings
posit a mechanism whereby signaling via α3/α5/β4-containing nAChRs promotes lung
carcinogenesis.
Keywords: nicotinic acetylcholine receptor, ligand-gated ion channel, lung cancer, small cell lung carcinoma,
CHRNA5
INTRODUCTION
Lung cancer remains the leading cause of cancer-related deaths
worldwide (WHO, 2011). Despite considerable research efforts to
elucidate the molecular underpinnings of the disease, the 5-year
survival rate for lung cancer has not changed appreciably over the
past three decades and persists at a dismal 15%. The two major
types of lung cancer are non-small cell lung carcinoma (NSCLC)
and SCLC. The former consists of a heterogeneous group of
tumors that account for 80% of lung cancer cases while the latter
is less common (15–20% of cases) but is particularly aggressive
(Rom et al., 2000; Sandler, 2003). SCLC is characterized by rapid
growth and early dissemination resulting in an extremely poor
prognosis for which no effective treatments are currently available
(Rudin et al., 2008).
Cigarette smoking is the major risk factor associated with
lung cancer. This is not surprising given that tobacco contains
∼250 damaging chemicals and ∼50 carcinogens (Hecht, 1999).
In the United States alone, over 45 million adults continue to
smoke while globally, 10 million cigarettes are sold every minute,
making tobacco use the leading cause of preventable deaths
(WHO, 2011). Prevention efforts are hampered, however, by the
Abbreviations: NSCLC, non-small cell lung carcinoma; SCLC, small cell lung
carcinoma; ACh, acetylcholine; nAChRs, nicotinic acetylcholine receptors; NNK, 4-
(methylnitrosamino)-1-(3-pyridyl)-1-butanone; GWAS, genome-wide association
studies.
strong reinforcing effects of nicotine, the primary psychoactive
component in tobacco.
Nicotine’s effects are mediated by nAChRs that are expressed
in the reward circuitry and other areas of the brain (Albuquerque
et al., 2009). nAChRs are also activated by the endogenous lig-
and acetylcholine (ACh), hence their name. Additionally, nAChRs
are activated by the nitrosamine 4-(methylnitrosamino)-1-(3-
pyridyl)-1-butanone (NNK), the most potent carcinogen in
tobacco (Schuller, 2007). Receptor activation allows the flow of
sodium, potassium and calcium ions down their electrochemical
gradients.
nAChRs are composed of transmembrane subunits that share
a common evolutionary origin (Le Novere et al., 2002). In
mammalian systems, these subunits are encoded by eleven
genes located across different chromosomes (Table 1). The genes
encoding the human α3, α5, and β4 subunits are found in a
gene cluster in chromosome 15q24 and are thought to be both
independently and coordinately regulated (Boulter et al., 1990;
Scofield et al., 2008). The α3 subunit is usually co-expressed with
the β4 subunit while α5 serves as an auxiliary subunit, whose
incorporation modifies the calcium permeability of the receptor
and its affinity to and desensitization by agonists (Ramirez-
Latorre et al., 1996; Yu and Role, 1998). α3β4-containing nAChRs
exhibit lower affinity for nicotine and are less desensitized by
it, suggesting that this receptor subtype may mediate nico-
tine’s rewarding effects after high affinity nAChR subtypes have
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been desensitized (Paradiso and Steinbach, 2003; Rose, 2007).
Moreover, α3β4α5 nAChRs are thought to play a role in nicotine
withdrawal and consistently, are highly expressed in brain regions
associated with nicotine withdrawal, such as the medial habenula
and the interpeduncular nucleus (Damaj et al., 2003; Salas et al.,
2009).
Multiple genome-wide association studies (GWAS) have
implicated the CHRNB4/A3/A5 locus in nicotine dependence and
lung cancer (Amos et al., 2008; Hung et al., 2008; Thorgeirsson
et al., 2008). A particularly interesting variant in this locus is
the non-synonymous single nucleotide polymorphism (SNP) that
lies in the fifth exon of CHRNA5 (rs16969968). This variant
encodes a change from an aspartic acid to an asparagine residue
at amino acid position 398 (D398N). The asparagine risk allele
is associated with decreased maximal response to agonists, indi-
cating altered receptor function (Bierut et al., 2008; George et al.,
2012). Additionally, the genotype in this locus appears to corre-
late with mRNA levels suggesting that rs16969968 may influence
CHRNA5 expression as well (Falvella et al., 2009; Wang et al.,
2009). In α3β4α5 nAChRs, the 398 residue also lies close to a
β4 residue that is necessary for β4′s ability to increase nicotine-
evoked currents, which subsequently leads to nicotine aversion
(Frahm et al., 2011). Notably, this increase in current is max-
imally competed by the D398N variant, resulting in reversal of
nicotine aversion. Altogether, these results support the functional
relevance of the rs16969968 variant.
The association of nAChR variants with both nicotine depen-
dence and lung cancer susceptibility prompts two hypotheses
regarding the role of nAChRs in lung cancer. One hypothesis
is that nicotine mainly influences nAChRs in the brain, such
that increased levels of nicotine dependence consequently lead
to greater exposure to tobacco carcinogens and to lung cancer
development (Le Marchand et al., 2008). Consistently, α3, α5,
and β4 nAChR subunits are predominantly expressed in select
neural circuits that control nicotine intake in rodent nicotine
dependence models (Fowler et al., 2011; Frahm et al., 2011).
An alternative hypothesis is that the association between nAChR
Table 1 | Chromosomal locations of genes encoding nAChR subunits.
Subunit* Gene Chromosome location**
Mouse Rat Human
α2 CHRNA2 14 15p12 8p21
α3 CHRNA3 9 8q24 15q24
α4 CHRNA4 2 3q43 20q13.2-q13.3
α5 CHRNA5 9 8q24 15q24
α6 CHRNA6 8 16q12.3 8p11.21
α7 CHRNA7 7 1q22 15q14
α9 CHRNA9 5 14p11 4p14
α10 CHRNA10 7 1q32 11p15.5
β2 CHRNB2 3 2q34 1q21.3
β3 CHRNB3 8 16q12.3 8p11.2
β4 CHRNB4 9 8q24 15q24
*α8 is expressed only in avian species.
**Summarized from the Entrez Gene Database (Maglott et al., 2011).
variants and lung cancer is direct, in that altered nAChR function,
as encoded by risk alleles, promote carcinogenic processes in the
lungs and airway tissues (Schuller, 2009). The following sections
discuss evidence in the literature as well as primary data that
support a direct role for nAChRs in lung cancer.
EXPRESSION AND FUNCTION OF nAChRs IN LUNG CANCER
The first hint that nAChRs play a direct role in lung cancer
comes from several studies demonstrating nAChR expression
in several types of cancers (Table 2). In lung cancer, we have
detected the expression of several nAChR subunit genes, in par-
ticular CHRNA3, CHRNA5, and CHRNB4 (Improgo et al., 2010).
Differences in nAChR gene expression between smokers and
non-smokers have also been reported (Lam et al., 2007).
Another line of evidence stems from studies showing that
nAChR ligands promote several hallmarks of cancer (Hanahan
and Weinberg, 2000; Schuller, 2009). Nicotine induces cell pro-
liferation in lung cancer cells via protein kinase C (Schuller, 1989;
Codignola et al., 1994) and Akt (West et al., 2003; Tsurutani et al.,
2005) activation. Nicotine’s carcinogenic metabolites have also
been shown to promote cell proliferation in lung cancer cells via
serotonin-induced stimulation of the Raf-1/MAPK/c-myc path-
way (Schuller and Orloff, 1998; Jull et al., 2001) and the Akt
pathway (West et al., 2003; Tsurutani et al., 2005).
In addition, nicotine has been shown to inhibit apoptosis by
phosphorylation of Bcl-2 family members (Jin et al., 2004a).
Apoptotic evasion potentially contributes to nicotine-induced
chemoresistance (Maneckjee and Minna, 1990, 1994). Similarly,
Table 2 | Types of cancer cells expressing nAChR subunits.
Cancer type nAChR subunits References
Cervical cancer α5, α7, α9 Calleja-Macias
et al., 2009
Colon cancer α7 Ye et al., 2004
Leukemia α2, α3, α5, α6, α7, α9, β2, β4 Sato et al., 1999;
Chernyavsky
et al., 2009
Lung cancer: NSCLC α3, α4, α5, α6, α7, α9, β2, β4 West et al., 2003;
Tsurutani et al.,
2005; Lam et al.,
2007; Improgo
et al., 2010
Lung cancer: SCLC α3, α5, α7, α9 β2, β4 Codignola et al.,
1994; Song et al.,
2003; Improgo
et al., 2010
Mesothelioma α7 Trombino et al.,
2004
Medulloblastoma α7 Siegel and Lukas,
1988
Neuroblastoma α3, β4 Lukas, 1993
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FIGURE 1 | CHRNA3, CHRNA5, and CHRNB4 depletion decreases SCLC
cell growth. DMS-53 cells were treated with three distinct CHRNA3,
CHRNA5, and CHRNB4 siRNAs or a negative control siRNA (Applied
Biosystems). (A) Quantitative RT-PCR was performed to determine mRNA
levels upon knockdown. (B) A bioluminescence-based cell viability assay
was performed to determine the effect of siRNA treatment on SCLC cell
viability (∗∗∗p < 0.001, ANOVA, Tukey post-hoc test). (C) CHRNA5 mRNA
levels in DMS-53 cells stably expressing a non-silencing shRNAmir or two
CHRNA5 shRNAmirs (Open Biosystems). shRNAmirs were transduced into
DMS-53 cells using a lentiviral delivery system for stable expression (Open
Biosystems Trans-Lentiral Packaging System). (D) DMS-53 cells stably
expressing a non-silencing shRNAmir or two CHRNA5 shRNAmirs were
subcutaneously injected into the hind flanks of athymic nude mice. Tumors
were harvested after 2 months (representative images shown). Tumor size
(E) and weight (F) were significantly lower in samples treated with
CHRNA5 shRNAmirs vs the non-silencing control (∗p < 0.05; ∗∗p < 0.01,
ANOVA, Tukey post-hoc test).
NNK inhibits apoptosis by Bcl-2 phosphorylation (Jin et al.,
2004b). Moreover, both nicotine and NNK promote cell survival
via the NF-kB pathway (Tsurutani et al., 2005).
Intriguingly, the complete cholinergic system is expressed and
functional in lung cells, where ACh acts both as an autocrine
and paracrine growth factor (Song et al., 2003; Proskocil et al.,
2004). Once activated, this growth loop may provide endogenous
mitogenic signaling without further nicotine activation. Such a
mechanism may explain residual risk for lung cancer even after
smoking cessation.
ACh is also thought to act as a pro-angiogenic signal via
autocrine and paracrine signaling in endothelial cells (Heeschen
et al., 2002). Nicotine promotes angiogenesis in a PI3-kinase and
FIGURE 2 | Pharmacological activation or inhibition of nAChRs
modulates SCLC growth. (A) DMS-53 cells were treated daily for 1 week
with 1μM nicotine or 2μM α-conotoxin AuIB. Cell viability assays show
that nicotine increases while AuIB decreases SCLC cell viability (values
normalized to saline control; ∗p < 0.05, ∗∗p < 0.01). (B) DMS-53 cells were
injected subcutaneously into the hind flanks of athymic nude mice. Mice
were then implanted with osmotic minipumps that delivered either saline
or 24mg/kg of nicotine daily. Tumors were harvested after 1 month
(representative images shown). (C,D). Chronic nicotine exposure increased
both tumor size and weight (∗∗p < 0.01, Student’s t-test).
MAPK-dependent manner (Heeschen et al., 2001). Moreover,
nicotine and its metabolite cotinine have been shown to up-
regulate the expression of the pro-angiogenic factor VEGF
(Conklin et al., 2002).
Many of these cancer-promoting processes are abrogated by
pan-nAChR or subtype-selective antagonists. Nicotine-induced
cell proliferation via fibronectin up-regulation can be abolished
by α-BTx (Zheng et al., 2007). Both α-BTx and the non-selective
nAChR inhibitor, mecamylamine, also hinder angiogenic growth
in vitro (Heeschen et al., 2002). Additionally, nicotine-induced
Akt activation and airway cell transformation can be inhib-
ited by the α4β2-selective antagonist, DHβE (West et al., 2003).
These observations collectively indicate that many of the above
cancer-related processes are mediated by nAChRs.
CHRNA3/A5/B4 IN SCLC
Given the GWAS association between the CHRNB4/A3/A5 locus
and lung cancer risk, we pursued the hypothesis that nAChRs
containing the α3, α5, and β4 subunits play a direct role in the
development of lung cancer. We focused on SCLC as we had
previously observed high expression of CHRNA5 and upregula-
tion of CHRNA3 and CHRNB4 in SCLC (Improgo et al., 2010).
We investigated the role of CHRNA3, CHRNA5, and CHRNB4 in
SCLC by silencing the expression of these three genes in the SCLC
cell line, DMS-53. Three distinct siRNAs against each gene were
used (Figure 1A). We assessed the effect of knockdown using a
bioluminescence-based cell viability assay as previously described
(Improgo et al., 2011). All the siRNAs that yielded > 90%
knockdown levels produced corresponding decreases in SCLC cell
viability (n = 5 each, Figure 1B), suggesting that expression of
CHRNA3, CHRNA5, and CHRNB4 is vital for SCLC cell viability,
at least in the context of the DMS-53 cell line.
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The two siRNAs that yielded the least knockdown (CHRNA5
a and c) did not significantly affect cell viability, suggesting
that certain CHRNA5 depletion thresholds may need to be
reached to obtain an observable phenotype. To therefore obtain
more robust silencing, we utilized shRNAmirs, hairpins that
are designed with flanking miRNA sequences that can harness
the cell’s endogenous RNAi machinery and promote more effi-
cient knockdowns. In addition, we introduced these shRNAmirs
to DMS-53 cells via lentiviral delivery to allow stable expres-
sion. For a more physiological approach, we used a tumor
xenograft model for in vivo propagation of tumors. Cells were
implanted into immunocompromised mice and tumor growth
was monitored. CHRNA5 shRNAmir A treatment (n = 5) caused
a 59% decrease in CHRNA5 levels while CHRNA5 shRNAmir
B treatment (n = 9) caused a 66% decrease in mRNA lev-
els (Figure 1C). Quite strikingly, tumor size and tumor weight
(Figures 1D–F) were significantly lower in cells treated with the
CHRNA5 shRNAmirs vs. the non-silencing shRNAmir control
(n = 9). These results further support the in vitro data described
above.
We next tested the effect of nAChR ligands on SCLC cell viabil-
ity. Using the same bioluminescence assay as above, we observed
that nicotine treatment increased SCLC cell viability (Figure 2A),
consistent with aforementioned reports. To perform the converse
experiment, we utilized the α3β4-selective ligand, α-conotoxin
AuIB. α-conotoxins are derived from the venom of cone snails, a
valuable source for disulfide-bonded peptides that target nAChRs
in a highly subtype-selectivemanner (Azam andMcIntosh, 2009).
α-conotoxin AuIB, in particular, was isolated from the snail-
eating cone Conus aurilicus and blocks α3β4 nAChRs with >
100-fold higher potency compared to other nAChR subtypes (Luo
et al., 1998). Treatment with α-conotoxin AuIB led to decreased
viability of DMS-53 cells (Figure 2A), indicating that functional
α3β4 nAChRs are present in SCLC cells and are important for the
maintenance of SCLC cell viability. In agreement with our genetic
approach, this pharmacological approach suggests that activation
and blockade of α3α5β4 nAChRs modulates SCLC cell viability.
We then tested the effect of chronic nicotine treatment on
tumor growth in vivo. We used osmotic minipumps to deliver
nicotine as these devices allow continued dosing of drugs while
eliminating repeated injections (Salas et al., 2004). Using the same
xenograft tumor model as above, we found that chronic nicotine
treatment increased tumor size and weight in vivo compared to
saline controls (Figures 2B–D). This is in line with previous find-
ings showing that nicotine promotes tumor growth in various
in vivo models (Davis et al., 2009; Al-Wadei et al., 2012).
Our results show that CHRNA3, CHRNA5, and CHRNB4
expression is critical for SCLC cell viability. These findings
lend mechanistic support to the correlative link between the
CHRNB4/A3/A5 locus and lung cancer susceptibility. That
α3β4α5 nAChRs play a direct role in lung cancer, in addition
to their role in the brain, points to the pleiotropic function of
these genes. Along with published reports, our work suggests a
mechanism by which cholinergic signaling via α3β4α5 nAChRs
promotes SCLC growth. Though this may raise questions regard-
ing the use of nicotine-based smoking cessation approaches,
it also indicates the potential of nAChR antagonists for SCLC
therapy.
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